Gensight Biologics SA
PAR:SIGHT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.2815
0.522
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gensight Biologics SA
Gensight Biologics SA
Intangible Assets
Gensight Biologics SA
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gensight Biologics SA
PAR:SIGHT
|
Intangible Assets
€66k
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Intangible Assets
€24.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Intangible Assets
€46.9m
|
CAGR 3-Years
306%
|
CAGR 5-Years
115%
|
CAGR 10-Years
85%
|
|
|
Inventiva SA
PAR:IVA
|
Intangible Assets
€451k
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Intangible Assets
€37.1m
|
CAGR 3-Years
100%
|
CAGR 5-Years
34%
|
CAGR 10-Years
11%
|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Intangible Assets
€45.2m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
See Also
What is Gensight Biologics SA's Intangible Assets?
Intangible Assets
66k
EUR
Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Intangible Assets amounts to 66k EUR.
What is Gensight Biologics SA's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
-17%
Over the last year, the Intangible Assets growth was -18%. The average annual Intangible Assets growth rates for Gensight Biologics SA have been -18% over the past three years , -17% over the past five years .
You don't have any saved screeners yet
